Shots:
- The P-III SELECT-PsA 1 & 2 trials evaluate Rinvoq (15/30mg) vs PBO in patients with active PsA & axial involvement who have a history of intolerance or inadequate response to one non-biologic & biologic DMARD
- The results showed a greater clinical response related to axial across both studies compared to Humira across all BASDAI & ASDAS EPs in SELECT-PsA 1 @24wks. & proportion of patients achieve ASDAS CII (69.8% vs 54.1%). The safety profile was consistent with previously reported studies & no new safety risks were observed
- Rinvoq (15mg) has received the US FDA’s approval for RA & EC’s approval for RA, PsA & AS. The therapy has received EC’s approval for 15 & 30mg doses to treat AD
Click here to read the full press release/ article | Ref: PR Newswire | Image: Pharma Live
The post AbbVie Presents New Post-Hoc Analyses of Rinvoq (upadacitinib) in P-III SELECT-PsA 1 & 2 trials for Active Psoriatic Arthritis at ACR 2021 first appeared on PharmaShots.
